Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Medicus Pharma announced it will focus the clinical development of SkinJect® solely on patients with Gorlin syndrome, a rare disease characterized by multiple basal cell carcinoma (BCC) lesions. This decision aligns with the company’s strategy to allocate resources to programs with the most compelling risk-adjusted potential. The company is pursuin…